Prescription Dermatology

Upadacitinib (RINVOQ)

Oral JAK1 inhibitor for rapid itch and AD control

Duration

経口1 days1 sessions

Downtime

なし

Sessions

継続oral (定期検査)

About This Treatment

Upadacitinib is an oral selective JAK1 inhibitor used for moderate-to-severe atopic dermatitis, often producing rapid itch and disease control.

It requires JAK-class risk screening and monitoring for infection, zoster, thrombosis, lipids, liver enzymes and malignancy risk.

JAK1 pathway inhibition dampens cytokine signaling related to inflammation and itch, including IL-4/IL-13/IL-31 pathways.

General indication (see detailed description)

Measure Up trials showed itch improvement as early as week 1 and sustained EASI/patient-reported improvements through week 16.

Measure Up investigators (2024)

Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis. Dermatol Ther

Clinical improvement was reported in this study (see original paper for details).

Real-world review authors (2024)

Practical use of upadacitinib in severe atopic dermatitis. Clin Cosmet Investig Dermatol

Clinical improvement was reported in this study (see original paper for details).

Serious infection, zoster, acne, thrombosis, lipid/liver enzyme elevations and pregnancy precautions require screening and labs.

Start with an AI skin analysis to check your current skin condition